Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

By converting immunologically 'cold' tumours into 'hot' ones, MB-108 may enhance the efficacy of the MB-101 CAR-T cell ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...